Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer

Alessandro Antonelli,Guido Bocci,Concettina La Motta,Silvia Martina Ferrari,Poupak Fallahi,Anna Fioravanti,Stefania Sartini,Michele Minuto,Simona Piaggi,Alessandro Corti,Greta Alì,Piero Berti,Gabriella Fontanini,Romano Danesi,Federico Da Settimo,Paolo Miccoli

Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer

2011

Alessandro Antonelli
Guido Bocci
Concettina La Motta
Silvia Martina Ferrari
Poupak Fallahi
Anna Fioravanti
Stefania Sartini
Michele Minuto
Simona Piaggi
Alessandro Corti
Greta Alì
Piero Berti
Gabriella Fontanini
Romano Danesi
Federico Da Settimo
Paolo Miccoli

The antitumoral activity of two new “pyrazolo[3,4-d]pyrimidine” compounds (CLM3, CLM29) in vitro, and of CLM3 in vivo, in dedifferentiated papillary thyroid cancer has been shown.

Keywords:

Pyrimidine
Pyrazolopyrimidine
In vivo
Thyroid cancer
Endocrinology
Tyrosine kinase
Diabetes mellitus
In vitro
Cancer research
Internal medicine
Medicine
Papillary thyroid cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations